An Improved Manufacturing Method for Infusible Extracellular Matrix Materials to Enable Efficient Scale-Up, Improved Efficacy, and Clinical Translation

Decellularized extracellular matrix (ECM) materials are widely used in tissue engineering and regenerative medicine due to their bioactive properties. To address the challenges in manufacturing infusible extracellular matrix (iECM) materials, a new method utilizing depth filtration and tangential flow filtration (DF-TFF) was developed. This method aims to improve manufacturing efficiency, increase iECM concentration, and enhance clinical translation.

The researchers compared iECM made with DF-TFF to that made with conventional centrifugation, dialysis, and filtration (C-D-F) methods. The results showed that iECM produced using DF-TFF had similar properties and could be produced at higher concentrations. As a result, the researchers demonstrated that DF-TFF could lead to dose-dependent responses in acute myocardial infarction (MI) porcine models and mouse multiple organ dysfunction syndrome (MODS) models.

Furthermore, DF-TFF allowed for the production of iECM from alternative tissue sources, providing flexibility in sourcing materials. By implementing this improved manufacturing method, the study highlights the potential for enhanced production time, scalability, compliance with current good manufacturing practices (cGMP), and increased doses of iECM.

These advancements pave the way for future clinical applications and additional preclinical studies, ultimately advancing the field of tissue engineering and regenerative medicine.